Click here to hear insights from EDBI’s Head of Emerging Technology, Dr Basil Lui on Panel: Investors Perspectives on Autonomous Mobility.
Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)
- 19 10 2023
- |